Generic Tiering Requirement, Enhanced Oversight On Chronic Meds Proposed For Marketplace Plans
Executive Summary
Commercial health insurance plans governed by the Affordable Care Act would need to modify their formularies for 2024 with policies to avoid discriminatory coverage of four ‘chronic ... high-cost medical conditions’ as well as overpayment for generics, according to CMS proposals.
You may also be interested in...
CMS ‘Safe Harbor’ For Use Of Copay Accumulators In Private Insurance Challenged In Court
Patient groups ‘left with no choice’ but to challenge federal regulation allowing commercial payers to bar manufacturer assistance with drug costs from being counted toward deductibles and out-of-pocket spending caps.
Copay Accumulator-Type Programs Proposed For ACA Exchange Plans
Annual payment rule for individual and group plans governed by Affordable Care Act proposes excluding drug manufacturer-sponsored copay assistance from out-of-pocket caps and seeks comments on use of reference pricing.
Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.